NICORETTE

Compare NICORETTE  to:
Compare
Compare

Generic Name for NICORETTE

Nicotine polacrilex 2mg, 4mg; chewing gum; sugar-free; fresh mint, orange, or original flavor.

Legal Classification:

OTC

Manufacturer of NICORETTE

GlaxoSmithKline Pharmaceuticals

Indications for NICORETTE

Adjunct in smoking cessation therapy.

Adult dose for NICORETTE

Use 2mg if patient smoked <25 cigarettes/day; use 4mg if patient smoked >24 cigarettes/day. Chew 1 piece slowly and intermittently over 30 minutes every 1–2 hours for 6 weeks (at least 9 per day), then every 2–4 hours for 3 weeks, then every 4–8 hours for 3 weeks, then stop; max 24 pieces/day.

Children's dosing for NICORETTE

Not recommended.

Contraindications for NICORETTE

Concurrent smoking or use of other nicotine products. Temporomandibular joint disease.

Warnings/Precautions for NICORETTE

Avoid immediately post-MI, in arrhythmias, or in severe or worsening angina pectoris. Hypertension. Coronary artery or vasospastic disease. Diabetes. Peptic ulcer. Oropharyngeal inflammation. Dental problems exacerbated by chewing. Pregnancy (attempt non-drug treatment first). Nursing mothers.

Interactions for NICORETTE

Do not eat or drink for 15 minutes before and during use; avoid concomitant acidic foods and beverages. Smoking cessation potentiates theophylline, insulin, β-blockers, pentazocine, oxazepam, tricyclic antidepressants (e.g., imipramine), caffeine, acetaminophen, adrenergic antagonists (e.g., prazosin, labetalol), others. Smoking cessation antagonizes adrenergic agonists (e.g., isoproterenol, phenylephrine), others.

Adverse Reactions for NICORETTE

Trauma to oral mucosa, teeth and dental work; jaw ache, GI upset, hiccups, dizziness, palpitations, hypertension.

How is NICORETTE supplied?

Starter kit—108 (w. educational materials)
Refill—48

Related Disease:

Smoking

Related Resources

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Marketing approval filed with FDA for Ariva-BDL as first modified risk tobacco product

February 22, 2010

Star Scientific announced that it has filed an application with the FDA for approval to market Ariva-BDL as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009.

FDA warns against use of electronic cigarettes

July 23, 2009

The FDA has notified healthcare professionals and patients that a laboratory analysis of electronic cigarette cartridge samples has found that they contain carcinogens (eg, nitrosamines) and diethylene glycol, a toxic chemical found in antifreeze.

Generic fruit and cinnamon flavored nicotine gum approved

July 08, 2009

The FDA has approved Watson's over-the-counter nicotine polacrilex gum in coated fruit and cinnamon flavors, the generic equivalent of GlaxoSmithKline Consumer Healthcare's smoking cessation aid, Nicorette Fruit Chill and Cinnamon Surge Coated gums.

Additional warnings for varenicline and bupropion

July 01, 2009

The FDA has notified healthcare professionals and patients that it has required manufacturers of varenicline (Chantix, from Pfizer) and bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL, and Zyban, from GlaxoSmithKline) to add new Boxed Warnings to the product labeling and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions